Cytek Biosciences CTKB Institutional Ownership

Cytek Biosciences, Inc. (NASDAQ:CTKB) has 157 institutional investors with active 13F positions as of June 2026.

• Collectively, these holders controlled 63.8% of Cytek Biosciences's outstanding shares in June 2026, down from 66.1% in March 2026.
• They increased total shares held in Cytek Biosciences by 1.98% from last quarter, and the number of investors in CTKB stayed flat annually.
• Among the 157 funds, 76 bought more Cytek Biosciences shares, 64 sold down, and 17 held their ground.
• In total, institutional investors held 82.64Mn shares in Cytek Biosciences as of June 2026, up by 1.61Mn shares quarter on quarter, and up 4.97Mn shares year over year.
• BlackRock, Inc. leads ownership in CTKB with 9.58Mn shares as of June 30, 2026, equal to 7.4% of outstanding shares.
• The largest buyers of Cytek Biosciences for the quarter ending June 2026 were MILLENNIUM MANAGEMENT LLC (3.05Mn), Boston Partners (1.86Mn), Sixth Street Partners Management Company, L.P. (1.07Mn), ACADIAN ASSET MANAGEMENT LLC (977.06K), JANE STREET GROUP, LLC (906.16K).
• Top sellers of CTKB stock for the quarter ending June 2026 included BlackRock, Inc. (7.43Mn), State Street Corp (1.56Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (1.17Mn), Morgan Stanley (1.02Mn), Topline Capital Management, LLC (781.03K).
• According to Business Quant data, leading holders of CTKB for June 2026 are BlackRock, Inc. (9.58Mn), MILLENNIUM MANAGEMENT LLC (9.34Mn), Boston Partners (7.66Mn), HHLR ADVISORS, LTD. (6.66Mn), Topline Capital Management, LLC (6.28Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.94Mn), GEODE CAPITAL MANAGEMENT, LLC (3.06Mn), DIMENSIONAL FUND ADVISORS LP (2.62Mn), State Street Corp (2.57Mn), Goldman Sachs Group Inc (2.17Mn).